Activation of the CXCL12/CXCR4 signaling axis may drive vascularization of the ovine placenta

被引:31
|
作者
Quinn, K. E. [1 ]
Ashley, A. K. [1 ]
Reynolds, L. P. [2 ]
Grazul-Bilska, A. T. [2 ]
Ashley, R. L. [1 ]
机构
[1] New Mexico State Univ, Dept Anim & Range Sci, Las Cruces, NM 88003 USA
[2] N Dakota State Univ, Ctr Nutr & Pregnancy, Dept Anim Sci, Fargo, ND 58108 USA
基金
美国食品与农业研究所;
关键词
CXCL12; CXCR4; VEGF; Vascularization; Pregnancy; Sheep; STROMAL-DERIVED FACTOR-1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; MATERNAL-FETAL INTERFACE; CHEMOKINE RECEPTOR CXCR4; REGULATORY T-CELLS; EARLY-PREGNANCY; TH2; BIAS; FACTOR-I; ANGIOGENESIS; EXPRESSION;
D O I
10.1016/j.domaniend.2013.12.004
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
Early pregnancy, when most embryonic losses occur, is a critical period in which vital placental vascularization is established. Vascular endothelial growth factor (VEGF) is a potent inducer of angiogenesis, and factors that regulate VEGF function, expression, or both may ultimately affect vascularization. Activation of the C-X-C chemokine receptor type 4 (CXCR4) by its cognate ligand, C-X-C chemokine ligand 12 (CXCL12), increases VEGF synthesis and secretion, which in turn stimulates CXCL12 and CXCR4 production and this synergistic regulation may influence placental vascularization. We hypothesized that expression of CXCL12, CXCR4, select angiogenic factors, and their receptors would increase in placental tissues during early pregnancy and that treatment of ovine trophectoderm cells with CXCL12 would increase production of angiogenic factors. To test this hypothesis, maternal caruncle (CAR) and fetal extraembryonic membrane (FM) tissues were collected on days 18, 20, 22, 25, 26, and 30 of pregnancy and on day 10 of the estrous cycle (control, NP) to determine relative mRNA or protein expression of CXCL12 and CXCR4 and selected angiogenic factors. In CAR, expression of mRNA for CXCR4 increased on day 18, 20, 22, and 25 and CXCL12 increased on day 18 and 20 compared with NP ewes. CXCL12 protein followed a similar pattern in CAR tissue, with greater levels on day 20 than in NP tissue. Greater levels of fibroblast growth factor 2 (FGF2) mRNA was observed in CAR on day 20 of gestation than on day 30. In FM, CXCL12, CXCR4, angiopoietin 1, VEGF, and VEGF receptor 1 were enhanced with advancing pregnancy, whereas FGF2 and kinase insert domain receptor (or VEGF receptor 2) peaked on day 25. An increase in protein levels occurred on day.25 compared with day 20 in FM for CXCL12 and CXCR4, as well as a similar tendency for FGF2 protein. Both CXCL12 and CXCR4 are specifically localized to trophoblast cells and to the uterine luminal and glandular epithelium. Treatment of ovine trophectoderm cells with CXCL12 increased mRNA expression for VEGF and FGF2. The relationship between VEGF, FGF2, and the CXCL12/CXCR4 signaling underscores the potential role for this chemokine axis in driving placentation. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:11 / 21
页数:11
相关论文
共 50 条
  • [41] CXCL12 inhibits hair growth through CXCR4
    Zheng, Mei
    Oh, Sang Ho
    Choi, Nahyun
    Choi, Yong Jin
    Kim, Jino
    Sung, Jong-Hyuk
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 150
  • [42] CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway
    Liang, Zhongxing
    Brooks, Joann
    Willard, Margaret
    Liang, Ke
    Yoon, Younghyoun
    Kang, Seunghee
    Shim, Hyunsuk
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 359 (03) : 716 - 722
  • [43] The role of CXCL12/CXCR4/CXCR7 axis in cognitive impairment associated with neurodegenerative diseases
    Sarallah, Rojin
    Jahani, Shima
    Khaboushan, Alireza Soltani
    Moaveni, Amir Kian
    Amiri, Maryam
    Zolbin, Masoumeh Majidi
    BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2025, 43
  • [44] Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies
    Peled, Amnon
    Klein, Shiri
    Beider, Katia
    Burger, Jan A.
    Abraham, Michal
    CYTOKINE, 2018, 109 : 11 - 16
  • [45] CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma
    Werner, Thomas A.
    Forster, Christina M.
    Dizdar, Levent
    Verde, Pablo E.
    Raba, Katharina
    Schott, Matthias
    Knoefel, Wolfram T.
    Krieg, Andreas
    BRITISH JOURNAL OF CANCER, 2017, 117 (12) : 1837 - 1845
  • [46] Double-Edged Role of the CXCL12/CXCR4 Axis in Experimental Myocardial Infarction
    Liehn, Elisa A.
    Tuchscheerer, Nancy
    Kanzler, Isabella
    Drechsler, Maik
    Fraemohs, Line
    Schuh, Alexander
    Koenen, Rory R.
    Zander, Simone
    Soehnlein, Oliver
    Hristov, Mihail
    Grigorescu, Gabriela
    Urs, Andreea O.
    Leabu, Mircea
    Bucur, Ilie
    Merx, Marc W.
    Zernecke, Alma
    Ehling, Josef
    Gremse, Felix
    Lammers, Twan
    Kiessling, Fabian
    Bernhagen, Juergen
    Schober, Andreas
    Weber, Christian
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (23) : 2415 - 2423
  • [47] Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
    Cho, Byung-Sik
    Kim, Hee-Je
    Konopleva, Marina
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (02) : 248 - 257
  • [48] The CXCL12 (SDF-1)/CXCR4 Axis Is Essential for the Development of Renal Vasculature
    Takabatake, Yoshitsugu
    Sugiyama, Tatsuki
    Kohara, Hiroshi
    Matsusaka, Taiji
    Kurihara, Hidetake
    Koni, Pandelakis A.
    Nagasawa, Yasuyuki
    Hamano, Takayuki
    Matsui, Isao
    Kawada, Noritaka
    Imai, Enyu
    Nagasawa, Takashi
    Rakugi, Hiromi
    Isaka, Yoshitaka
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (08): : 1714 - 1723
  • [49] Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer
    Nazari, Alireza
    Khorramdelazad, Hossein
    Hassanshahi, Gholamhossein
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (06) : 991 - 1000
  • [50] CXCR4/CXCL12 axis: "old" pathway as "novel" target for anti-inflammatory drug discovery
    Lu, Liuxin
    Li, Junjie
    Jiang, Xiaoying
    Bai, Renren
    MEDICINAL RESEARCH REVIEWS, 2024, 44 (03) : 1189 - 1220